| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
|
| [2] |
Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J National Cancer Center, 2022, 2(1): 1-9.
|
| [3] |
Scheer MGW, Sloots CEJ, van der Wilt GJ, et al. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases[J]. Ann Oncol, 2008, 19(11): 1829-1835.
|
| [4] |
Ng K, May FP, Schrag D. US preventive services task force recommendations for colorectal cancer screening: forty-five is the new fifty[J]. JAMA-J Am Med Assoc 2021, 325(19): 1943-1945.
|
| [5] |
国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南(2020, 北京)[J]. 中华肿瘤杂志, 2021, 43(1): 16-38.
|
| [6] |
马志刚, 朱晓麟, 马丽红, 等. 基于多靶点粪便FIT-DNA联合检测技术的结直肠癌早期筛查结果分析[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(6): 616-621.
|
| [7] |
Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know[J]. Gut, 2015, 64(8): 1327-1337.
|
| [8] |
Li JN, Yuan SY. Fecal occult blood test in colorectal cancer screening[J]. J Dig Dis, 2019, 20(2): 62-64.
|
| [9] |
Clark G, Strachan JA, Carey FA, et al. Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme[J]. Gut, 2021, 70(1): 106-113.
|
| [10] |
Zackular JP, Rogers MAM, Ruffin MT, et al. The human gut microbiome as a screening tool for colorectal cancer[J]. Cancer Prev Res, 2014, 7(11): 1112-1121.
|
| [11] |
Zou J, Xiao Z, Wu Y, et al. Noninvasive fecal testing for colorectal cancer[J]. Clin Chim Acta, 2022, 524: 123-131.
|
| [12] |
Peng SM, Hsu WF, Wang YW, et al. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme[J]. Gut, 2021, 70(7): 1318-1324.
|
| [13] |
Nicholson BD, James T, Paddon M, et al. Faecal immunochemical testing for adults with symptoms of colorectal cancer attending English primary care: a retrospective cohort study of 14 487 consecutive test requests[J]. Aliment Pharmacol Ther, 2020, 52(6): 1031-1041.
|
| [14] |
马晨曦, 关旭, 王松, 等. 粪便DNA检测技术在结直肠癌筛查中的应用现状及展望[J]. 中华胃肠外科杂志, 2019, 22(5): 491-494.
|
| [15] |
Carethers JM. Fecal DNA testing for colorectal cancer screening[J]. Annu Rev Med, 2020, 71: 59-69.
|
| [16] |
Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors[J]. Science (New York, NY), 1992, 256(5053): 102-105.
|
| [17] |
Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel[J]. Gastroenterology, 2000, 119(5): 1219-1227.
|
| [18] |
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14): 1287-1297.
|
| [19] |
Redwood DG, Asay ED, Blake ID, et al. Stool DNA testing for screening detection of colorectal neoplasia in alaska native people[J]. Mayo Clin Proc, 2016, 91(1): 61-70.
|
| [20] |
Redwood DG, Dinh TA, Kisiel JB, et al. Cost-effectiveness of multitarget stool dna testing vs colonoscopy or fecal immunochemical testing for colorectal cancer screening in alaska native people[J]. Mayo Clin Proc, 2021, 96(5): 1203-1217.
|
| [21] |
Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia[J]. Gastroenterology, 2016, 151(3): 427-439.
|
| [22] |
Yang TW, Lee WH, Tu SJ, et al. Enterotype-based analysis of gut microbiota along the conventional adenoma-carcinoma colorectal cancer pathway[J]. Sci Rep, 2019, 9(1): 10923.
|
| [23] |
Yachida S, Mizutani S, Shiroma H, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer[J]. Nat Med, 2019, 25(6): 968-976.
|
| [24] |
Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia[J]. Gut, 2017, 66(8): 1441-1448.
|
| [25] |
Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(11): 690-704.
|
| [26] |
Wu YQ, Jiao N, Zhu RX, et al. Identification of microbial markers across populations in early detection of colorectal cancer[J]. Nature Communications, 2021, 12(1): 13.
|
| [27] |
Coker OO, Liu C, Wu WKK, et al. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers[J]. Microbiome, 2022, 10(1): 12.
|
| [28] |
Jain S, Maque J, Galoosian A, et al. Optimal strategies for colorectal cancer screening[J]. Curr Treat Options Oncol, 2022, 23(4): 474-493.
|
| [29] |
Slaby O. Non-coding RNAs as biomarkers for colorectal cancer screening and early detection[J]. Adv Exp Med Biol, 2016, 937: 153-170.
|
| [30] |
Wu CW, Ng SC, Dong YJ, et al. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma[J]. Clin Cancer Res, 2014, 20(11): 2994-3002.
|
| [31] |
Duran-Sanchon S, Moreno L, Auge JM, et al. Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer[J]. Gastroenterology, 2020, 158(4): 947-957.
|
| [32] |
Uppara M, Adaba F, Askari A, et al. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer[J]. World J Surg Oncol, 2015, 13: 48.
|
| [33] |
Lue A, Hijos G, Sostres C, et al. The combination of quantitative faecal occult blood test and faecal calprotectin is a cost-effective strategy to avoid colonoscopies in symptomatic patients without relevant pathology[J]. Ther Adv Gastroenterol, 2020, 13: 1756284820920786.
|
| [34] |
Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function[J]. Gut, 2021, 70(10): 1978-1988.
|
| [35] |
Komor MA, Bosch LJW, Coupe VMH, et al. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression[J]. J Pathol, 2020, 250(3): 288-298.
|
| [36] |
Shah MS, DeSantis TZ, Weinmaier T, et al. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer[J]. Gut, 2018, 67(5): 882-891.
|
| [37] |
Liang JQ, Li T, Nakatsu G, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer[J]. Gut, 2020, 69(7): 1248-1257.
|
| [38] |
Koga Y, Yamazaki N, Yamamoto Y, et al. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test[J]. Cancer Epidemiol Biomarkers Prev, 2013, 22(10): 1844-1852.
|
| [39] |
Duran-Sanchon S, Moreno L, Gomez-Matas J, et al. Fecal microRNA-based algorithm increases effectiveness of fecal immunochemical test-based screening for colorectal cancer[J]. Clin Gastroenterol Hepatol, 2021, 19(2): 323-330.
|
| [40] |
Wong MCS, Huang JJ, Wong YY, et al. The use of a non-invasive biomarker for colorectal cancer screening: a comparative cost-effectiveness modeling study[J]. Cancers, 2023, 15(3): 14.
|
| [41] |
Zhou H, Zhu LY, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer[J]. Molecular Cancer, 2022, 21(1): 21.
|
| [42] |
Zhou BT, Xu KL, Zheng X, et al. Application of exosomes as liquid biopsy in clinical diagnosis[J]. Signal Transduct Target Ther, 2020, 5(1): 14.
|
| [43] |
Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution[J]. Dig Dis Sci, 2015, 60(3): 609-622.
|
| [44] |
Nikolaou S, Qiu SY, Fiorentino F, et al. Systematic review of blood diagnostic markers in colorectal cancer[J]. Tech Coloproctology, 2018, 22(7): 481-498.
|
| [45] |
Marcuello M, Duran-Sanchon S, Moreno L, et al. Analysis of A 6-mirna signature in serum from colorectal cancer screening participants as non-invasive biomarkers for advanced adenoma and colorectal cancer detection[J]. Cancers, 2019, 11(10): 12.
|
| [46] |
Gao HL, Lv LB, Zhao WF, et al. Diagnostic accuracy of the multi-target stool DNA test in detecting colorectal cancer: A hospital-based study[J]. World J Gastrointest Oncol, 2023, 15(1): 102-111.
|
| [47] |
Zhong GC, Sun WP, Wan L, et al. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis[J]. Gastrointestinal Endoscopy, 2020, 91(3): 684-697.
|
| [48] |
Peterse EFP, Meester RGS, de Jonge L, et al. Comparing the cost-effectiveness of innovative colorectal cancer screening tests[J]. JNCI-J Natl Cancer Inst, 2021, 113(2): 154-161.
|
| [49] |
Cruz A, Carvalho CM, Cunha A, et al. Faecal diagnostic biomarkers for colorectal cancer[J]. Cancers, 2021, 13(21): 10.
|